|
Organogenesis Holdings Inc (NASDAQ: ORGO) |
|
Organogenesis Holdings Inc
ORGO's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Organogenesis Holdings Inc growth rates, revenue grew
by 6.12 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1853
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Organogenesis Holdings Inc 's net income grew by 289.36 % in III. Quarter 2024 year on year, above company average,
• More on ORGO's Growth
|
|
Organogenesis Holdings Inc realized a net loss in trailing twelve months.
Organogenesis Holdings Inc realized cash reduction of $ -0.03 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.02.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.
• More on ORGO's Valuation
|
|
|
|
|
Organogenesis Holdings Inc realized net loss in trailing twelve months.
Organogenesis Holdings Inc realized cash outflow of $ -0.03per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.02.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.
Organogenesis Holdings Inc Price to Book Ratio is at 1.66 lower than Industry Avg. of 88.81. and higher than S&P 500 Avg. of 0.02
• More on ORGO's Valuation
|
|
ORGO's Profitability Comparisons
|
Organogenesis Holdings Inc achieved increase in profitability, due to cost control. Operating Margin grew in III. Quarter 2024 to 5.42 %.
Organogenesis Holdings Inc net profit margin of 10.71 % is currently ranking no. 43 in Major Pharmaceutical Preparations industry, ranking no. 111 in Healthcare sector and number 1261 in S&P 500.
Profitability by Segment |
Total |
10.71 % |
|
|
Organogenesis Holdings Inc achieved increase in profitability, due to cost control. Operating Margin grew in III. Quarter 2024 to 5.42 %.
Organogenesis Holdings Inc net profit margin of 10.71 % is currently ranking no. 43 in Major Pharmaceutical Preparations industry, ranking no. 111 in Healthcare sector and number 1261 in S&P 500.
• More on ORGO's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com